The nation of Zimbabwe has turned down a major American healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's insistence on sensitive data.
This rejection became public following a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesperson later explained that the United States was requesting genetic material for scientific study and commercial gain but was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further dialogue to secure a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Implications
This rejection follows a comparable situation in Kenya, where a court halted a similar deal with the US following concerns were filed about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost transparency and responsibility.
Based on statements, 16 nations in Africa have to date signed these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our country would supply the basic resources for medical research without any certainty that the final treatments would be available to our people if a future pandemic emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our US partners on how subsequent co-operation could be structured in a way that respects the independence and dignity of each country."
Health Experts Response
Medical experts said it recognised the government's concerns, but urged that talks must proceed considering much of the country's Aids initiatives were funded by international support.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group commented.
This impasse underscores the ongoing tensions between receiving much-needed foreign assistance and protecting local interests in an ever more data-driven world.